Inovio Pharma
Stock
Stock
Ticker: INO
INO
Price
Price
CHART BY
Frequently asked questions
What is Inovio Pharma's market capitalization?
The market capitalization of Inovio Pharma is $86.74M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Inovio Pharma?
Inovio Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.176. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Inovio Pharma's stock?
Currently, 3 analysts cover Inovio Pharma's stock, with a consensus target price of $3.167. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Inovio Pharma?
Inovio Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$76.25M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Inovio Pharma?
Inovio Pharma has a free cash flow of -$80.78M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Inovio Pharma have, and what sector and industry does it belong to?
Inovio Pharma employs approximately 112 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Inovio Pharma's shares?
The free float of Inovio Pharma is 103.01M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $86.74M
- EPS (TTM)
- -$1.176
- Free Float
- 103.01M
- EBITDA (TTM)
- -$76.25M
- Free Cashflow (TTM)
- -$80.78M
Pricing
- 1D span
- $0.815$0.935
- 52W span
- $0.567$2.72
Analyst Ratings
The price target is $3.167 and the stock is covered by 3 analysts.
Buy
2
Hold
1
Sell
0
Information
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
- Employees
- 112
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- INO
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet